S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 5202 Reports
🤖 AI Analyzed
Recent
📄 Page 60 of 434
Veradermics, Inc
10-K March 30, 2026

Key Highlights

  • Developing VDPHL01, a non-hormonal oral pill for pattern hair loss.
  • Promising pilot study results with 90.5% of men showing improved hair coverage.
  • Successfully raised $115 million in IPO to fund Phase 2b and Phase 3 trials.
Read Analysis
🤖 AI Generated
Sensei Biotherapeutics, Inc.
10-K March 30, 2026

Key Highlights

  • Acquired Faeth Therapeutics to pivot focus toward metabolism-based cancer therap...
  • Lead drug candidate PIKTOR (FT-101) targets solid tumors with Phase 2 results ex...
  • Successfully raised $200 million in February 2026, extending the company's finan...
Read Analysis
🤖 AI Generated
Terns Pharmaceuticals, Inc.
10-K March 30, 2026

Key Highlights

  • Merck & Co. to acquire Terns Pharmaceuticals for $53.00 per share in cash.
  • The acquisition deal values Terns Pharmaceuticals at approximately $6.1 billion.
  • Terns continues clinical development of TERN-701 for leukemia pending deal closu...
Read Analysis
🤖 AI Generated
AEON Biopharma, Inc.
10-K March 30, 2026

Key Highlights

  • Focused development of ABP-450 for the $3.3 billion U.S. medical botulinum toxin...
  • Strategic pivot to prioritize cervical dystonia trials over migraine research to...
  • Significant reduction in annual net losses from $48.2 million to $12.8 million.
Read Analysis
🤖 AI Generated
PMGC Holdings Inc.
10-K March 30, 2026

Key Highlights

  • Pivot to industrial manufacturing with the acquisition of Pacific Sun Packaging ...
  • Development of EL-22, a high-potential biotech project targeting the weight-loss...
  • Established $21 million in annual revenue from new industrial manufacturing oper...
Read Analysis
🤖 AI Generated
Pasithea Therapeutics Corp.
10-K March 30, 2026

Key Highlights

  • PAS-004 shows promising safety profile with no serious side effects in early tri...
  • Strategic pivot to focus exclusively on PAS-004 to optimize cash runway.
  • Global clinical trial expansion into U.S., Australia, and South Korea to acceler...
Read Analysis
🤖 AI Generated
Aspire Biopharma Holdings, Inc.
10-K March 30, 2026

Key Highlights

  • Secured $15 million in financing to fund operations through late 2026.
  • Transitioning post-merger to streamline R&D and drug delivery systems.
  • Focusing on supplement sales growth to reduce reliance on share-based financing.
Read Analysis
🤖 AI Generated
Dragonfly Energy Holdings Corp.
10-K March 30, 2026

Key Highlights

  • Specializes in deep-cycle lithium-ion batteries for RVs, boats, and off-grid mar...
  • Actively developing proprietary solid-state battery technology to drive future g...
  • Maintains a strong brand presence under the Battle Born Batteries label.
Read Analysis
🤖 AI Generated
Sigma Lithium Corp
40-F March 30, 2026

Key Highlights

  • Strategic transition to in-house mining fleet to remove operational bottlenecks
  • Expansion roadmap targeting 766,000 tonnes of annual production capacity
  • Environmentally friendly production using 100% renewable energy and recycled wat...
Read Analysis
🤖 AI Generated
OneMedNet Corp
10-K March 30, 2026

Key Highlights

  • Transitioning from project-based revenue to a recurring subscription model via t...
  • Curating and de-identifying high-value medical data for pharmaceutical and medic...
  • Aggressive operational scaling to capture market share in the healthcare data in...
Read Analysis
🤖 AI Generated
Ero Copper Corp.
40-F March 30, 2026

Key Highlights

  • Transitioning from a single-mine producer to a multi-asset growth company.
  • Successful ramp-up of the Tucumã project driving significant revenue.
  • Strong corporate governance featuring executive clawback policies and independen...
Read Analysis
🤖 AI Generated
WinVest Acquisition Corp.
10-K March 30, 2026

Key Highlights

  • Trust account holds approximately $10.1 million in U.S. Treasury bonds.
  • Potential liquidation value of $10.10 per share if no merger occurs.
  • Strategic focus on acquiring companies in the financial technology or digital as...
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage